ライフサイエンスコーパス: type 1 diabetes mellitus

1 ody mass index, systolic blood pressure, and type 1 diabetes mellitus.

2 impaired cardiac energetics in subjects with type 1 diabetes mellitus.

3 -reperfusion injury using a porcine model of type 1 diabetes mellitus.

4 lets (API) was assessed in a murine model of type 1 diabetes mellitus.

5 ody mass index, systolic blood pressure, and type 1 diabetes mellitus.

6 may be a future treatment for patients with type 1 diabetes mellitus.

7 et transplantation for treatment of unstable type 1 diabetes mellitus.

8 ve therapy on retinopathy and nephropathy in type 1 diabetes mellitus.

9 al practice for assessing the risk of CVD in type 1 diabetes mellitus.

10 ultiple sclerosis, rheumatoid arthritis, and type 1 diabetes mellitus.

11 pheral tolerance, which is also defective in type 1 diabetes mellitus.

12 d therapy for select nonuremic patients with type 1 diabetes mellitus.

13 litating islet transplantation as a cure for type 1 diabetes mellitus.

14 e as a source of islets for the treatment of type 1 diabetes mellitus.

15 eatment of choice for selected patients with type 1 diabetes mellitus.

16 -based insulin gene-therapy for treatment of type 1 diabetes mellitus.

17 a different population of 2119 patients with type 1 diabetes mellitus.

18 loss of insulin production in patients with type 1 diabetes mellitus.

19 ation (PTX) improves lipids in patients with type 1 diabetes mellitus.

20 islet cell transplantation for treatment of type 1 diabetes mellitus.

21 of allogeneic islets of Langerhans to treat type 1 diabetes mellitus.

22 active protein, systolic blood pressure, and type 1 diabetes mellitus.

23 s for an improved treatment of patients with type 1 diabetes mellitus.

24 placement therapy for selected patients with type 1 diabetes mellitus.

25 onsidered a viable alternative treatment for type 1 diabetes mellitus.

26 ndent risk factors for progression of DSP in type 1 diabetes mellitus.

27 elevated serum creatinine concentrations, or type 1 diabetes mellitus.

28 r patients with renal failure resulting from type 1 diabetes mellitus.

29 ys a significant role in the pathogenesis of type 1 diabetes mellitus.

30 ia from a well-characterized animal model of type 1 diabetes mellitus.

31 promising target for beta-cell protection in type 1 diabetes mellitus.

32 es are under way to investigate their use in type 1 diabetes mellitus.

33 placement therapy for selected patients with type 1 diabetes mellitus.

34 ative retinopathy and other complications of type 1 diabetes mellitus.

35 e CD4(+) T cells are an essential feature of type 1 diabetes mellitus.

36 for severe vascular outcomes in persons with type 1 diabetes mellitus.

37 odes, among both adults and adolescents with type 1 diabetes mellitus.

38 5 days in 20 adults and 32 adolescents with type 1 diabetes mellitus.

39 ategy to restore euglycemia in patients with type 1 diabetes mellitus.

40 -term complications that are associated with type 1 diabetes mellitus.

41 le effect on glycemic control in adults with type 1 diabetes mellitus.

42 mune diseases such as multiple sclerosis and type 1 diabetes mellitus.

43 ovides a promising approach for treatment of type 1 diabetes mellitus.

44 reatic islets is of significant interest for type 1 diabetes mellitus.

45 n healthy control subjects and patients with type 1 diabetes mellitus.

46 duration, and limited to white persons with type 1 diabetes mellitus.

47 duced by 38%, 20%, and 40%, respectively, in type 1 diabetes mellitus.

48 resonance was obtained in 1017 patients with type 1 diabetes mellitus.

49 nopathy-candidiasis-ectodermal dystrophy and type-1 diabetes mellitus.

50 a cell destruction in pre-insulin-dependent (type 1) diabetes mellitus.

51 Subjects with type 1 diabetes mellitus (97% white, 45% female, mean ag

52 ythematosus, autoimmune thyroid disease, and type 1 diabetes mellitus, all of which are T cell-mediat

53 By contrast, in type 1 diabetes mellitus, alpha-cells lack constant acti

54 -mediated beta-cell dysfunction and death in type 1 diabetes mellitus, although the mechanisms are in

55 dney (PAK) transplantation, in patients with type 1 diabetes mellitus and end-stage kidney disease pr

56 glycemia and renal function in patients with type 1 diabetes mellitus and end-stage renal failure.

57 king insulin alone were classified as having type 1 diabetes mellitus and excluded.

58 igated in RA) have been associated with both type 1 diabetes mellitus and Graves' disease.

59 abolic effects of exenatide in subjects with type 1 diabetes mellitus and islet allograft dysfunction

60 In normotensive patients with type 1 diabetes mellitus and microalbuminuria, ACE inhib

61 Systemic organ-specific autoimmunities (type 1 diabetes mellitus and others) were present in 29

62 These factors are essential for the onset of type 1 diabetes mellitus and related complications.

63 ng HP eradication before 2005, patients with type 1 diabetes mellitus and those with unknown living r

64 1858T allele was separately associated with type 1 diabetes mellitus and with autoimmune thyroid dis

65 e important mediators of multiple sclerosis, type 1 diabetes mellitus, and rheumatoid arthritis.

66 We conclude that in patients with type 1 diabetes mellitus, anti-B cell mAb causes increas

67 Patients with type 1 diabetes mellitus are at increased risk of develo

68 for allogeneic islets of Langerhans to treat type 1 diabetes mellitus are discussed.

69 ystem autoimmunity, particularly early-onset type 1 diabetes mellitus, associated with manifestations

70 ify NPPEs of the intracellular domain of the type 1 diabetes mellitus-associated (type 1 DM-associate

71 eral renal hypoplasia and was diagnosed with type 1 diabetes mellitus at age 13 months.

72 incidence cohort followed from diagnosis of Type 1 diabetes mellitus at ages 0-29 (n = 577).

73 In type 1 diabetes mellitus, autoantibodies to insulin are

74 planted 26 adult patients with long standing type 1 diabetes mellitus between April 2000 and June 200

75 s more than MDI and SMBG did in persons with type 1 diabetes mellitus (between-group difference of ch

76 tore normoglycemia to patients with unstable type 1 diabetes mellitus, but long-term insulin independ

77 nitis, food allergy, allergic sensitization, type 1 diabetes mellitus, celiac disease, inflammatory b

78 ed in diseases such as rheumatoid arthritis, type 1 diabetes mellitus, Crohn's disease, and multiple

79 mpressive recent advance in the search for a type 1 diabetes mellitus cure.

80 outcomes when using kidneys from donors with type 1 diabetes mellitus (D1) or type 2 diabetes mellitu

81 thritis with a polyarticular course, in whom type 1 diabetes mellitus developed 5 months after the in

82 l contrast echocardiography in patients with type 1 diabetes mellitus (DM) and in healthy control sub

83 t has being associated with earlier onset of type 1 diabetes mellitus (DM) and islet graft failure.

84 seases such as rheumatoid arthritis (RA) and type 1 diabetes mellitus (DM) has been reported in indiv

85 this study was to examine the association of type 1 diabetes mellitus (DM) on the periodontal status

86 e polymorphisms (SNPs) within this gene with type 1 diabetes mellitus (DM), Graves' disease, rheumato

87 s from Argentina; rheumatoid arthritis (RA), type 1 diabetes mellitus (DM), primary Sjogren's syndrom

88 d, albeit inconsistently, in the etiology of type 1 diabetes mellitus (DM).

89 neuropathy, retinopathy, and nephropathy in type 1 diabetes mellitus (DM).

90 measured in C-peptide-negative patients with type 1 diabetes mellitus during insulin deprivation (n =

91 l symmetric neuropathy in 1172 patients with type 1 diabetes mellitus from 31 centers participating i

92 HLA-DQ2 (DQ2) allele with celiac disease and type 1 diabetes mellitus have been appreciated for a lon

93 risk of celiac disease and its overlap with type 1 diabetes mellitus have been identified.

94 trate that young subjects with uncomplicated type 1 diabetes mellitus have impaired myocardial energe

95 In adults with type 1 diabetes mellitus, HbA1c levels decreased more wi

96 Among youth with type 1 diabetes mellitus, higher adherence to the DASH d

97 Insulin-dependent or Type 1 diabetes mellitus (IDDM) has been associated with

98 ices were tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12h.

99 ave been associated with a decreased risk of type 1 diabetes mellitus in a retrospective study.

100 toantigen 69 kDa) is a protein implicated in type 1 diabetes mellitus in both the non-obese diabetic

101 e primary autoantigen triggering spontaneous type 1 diabetes mellitus in nonobese diabetic (NOD) mice

102 ructure, function, and scar in patients with type 1 diabetes mellitus in the Diabetes Control and Com

103 s metabolic control during the first year of type 1 diabetes mellitus in the majority of patients.

104 plays a role in autoimmune insulin-dependent type 1 diabetes mellitus in the nonobese diabetic mouse.

105 developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and

106 e autoreactive T cells from individuals with type 1 diabetes mellitus, including killing of human isl

107 osis, and dysfunction under the condition of type 1 diabetes mellitus induced by streptozotocin injec

108 Type 1 diabetes mellitus is a chronic autoimmune disease

109 Type 1 diabetes mellitus is a chronic autoimmune disease

110 Whether mortality in type 1 diabetes mellitus is affected following intensive

111 Type 1 diabetes mellitus is an autoimmune disease charac

112 Type 1 diabetes mellitus is associated with an increased

113 The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoi

114 The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte

115 Type 1 diabetes mellitus is believed to be due to the au

116 Type 1 diabetes mellitus is caused by the killing of ins

117 Type 1 diabetes mellitus is caused by the T cell mediate

118 Type 1 diabetes mellitus is characterized by the selecti

119 Type 1 diabetes mellitus is one of the most common chron

120 eight gain with diabetes mellitus therapy of type 1 diabetes mellitus is prospectively associated wit

121 remediate a diabetic phenotype in a model of type 1 diabetes mellitus is the first step in an effort

122 management programs benefit individuals with type 1 diabetes mellitus is unclear.

123 sure during early life in the development of type 1 diabetes mellitus is unclear.

124 ce on the pathogenesis of insulin-dependent (type 1) diabetes mellitus, it served as a prediabetes ma

125 D), Huntington disease (HD), juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/triso

126 improves skeletal muscle repair in mice with type 1 diabetes mellitus, leading us to hypothesize that

127 Twenty-five asymptomatic subjects with type 1 diabetes mellitus (mean age +/-1 SD 33+/-8 years)

128 d 1 or more coexisting autoimmune disorders: type 1 diabetes mellitus (n = 4), thyroid disease (n = 2

129 ibition among patients aged 18-56 years with type 1 diabetes mellitus of 1-15 years' duration.

130 s of macrophages and dendritic cells (DC) in type 1 diabetes mellitus of the NOD mouse by using dipht

131 to address the role of intensive therapy for type 1 diabetes mellitus on the onset and progression of

132 ated autoreactive T cells from patients with type-1 diabetes mellitus or rheumatoid arthritis (RA) ar

133 between epilepsy and 12 autoimmune diseases: type 1 diabetes mellitus, psoriasis, rheumatoid arthriti

134 e analysis of PRA status in 66 patients with type 1 diabetes mellitus recipient of islet allografts b

135 Intensive therapy in patients with type 1 diabetes mellitus reduced levels of sICAM-1 and i

136 Intensive diabetes mellitus therapy of type 1 diabetes mellitus reduces diabetes mellitus compl

137 A gene-therapy-based treatment of type 1 diabetes mellitus requires the development of a s

138 Similarly treated type 1 diabetes mellitus-resistant mouse strains develop

139 Type 1 diabetes mellitus results from the autoimmune des

140 olymorphism in PTPN22 has been implicated in type 1 diabetes mellitus, rheumatoid arthritis, Graves'

141 evascularization (RR, 1.8 [CI, 1.2 to 2.7]); type 1 diabetes mellitus (RR, 1.8 [CI, 1.1 to 3.0]) or p

142 Care for type 1 diabetes mellitus should both alleviate the physi

143 l perfusion reserve index in the longer-term type 1 diabetes mellitus subjects was significantly lowe

144 The type 1 diabetes mellitus subjects were divided into 2 ag

145 bility complex (MHC) that has been linked to type 1 diabetes mellitus susceptibility.

146 ciated with psoriasis, rheumatoid arthritis, type 1 diabetes mellitus, systemic lupus erythematosus,

147 Long-term data of patients with type 1 diabetes mellitus (T1D) after simultaneous islet-

148 morbidity of herpesviruses in patients with type 1 diabetes mellitus (T1D) enrolled in immunosuppres

149 Type 1 diabetes mellitus (T1D) is an autoimmune disease

150 Type 1 diabetes mellitus (T1D) is characterized by a hei

151 Type 1 diabetes mellitus (T1D) remains the most intensiv

152 Both the IGEs and type 1 diabetes mellitus (T1D) represent serious worldwi

153 n the pathogenesis of islet autoimmunity and type 1 diabetes mellitus (T1D), but previous studies did

154 in young adults are associated with risk of type 1 diabetes mellitus (T1D), we conducted a prospecti

155 sor of T-cell activation, is associated with type 1 diabetes mellitus (T1D).

156 reins, in particular tissue kallikrein-1, in type 1 diabetes mellitus (T1D).

157 QD on renal hyperfiltration in subjects with type 1 diabetes mellitus (T1D).

158 Insulin-dependent (type 1) diabetes mellitus (T1D) onset is mediated by ind

159 ears) and 11 otherwise healthy patients with type 1 diabetes mellitus (T1DM) (8 women, ages 36 +/- 10

160 ion of transplanted kidneys in patients with type 1 diabetes mellitus (T1DM) and end-stage renal dise

161 optimal therapeutic option for patients with type 1 diabetes mellitus (T1DM) and end-stage renal dise

162 Patients with type 1 diabetes mellitus (T1DM) and end-stage renal dise

163 ellitus, to compare DR rates for youths with type 1 diabetes mellitus (T1DM) and those with T2DM, and

164 e control on the prevention of neuropathy in type 1 diabetes mellitus (T1DM) and type 2 diabetes mell

165 We hypothesized that cognitive decrements in type 1 diabetes mellitus (T1DM) are associated with alte

166 Human type 1 diabetes mellitus (T1DM) arises through autoimmun

167 Islet transplantation can temporarily cure type 1 diabetes mellitus (T1DM) but requires simultaneou

168 VOC profiles may be present in children with type 1 diabetes mellitus (T1DM) during spontaneous hyper

169 Subjects with type 1 diabetes mellitus (T1DM) eventually develop insul

170 Patients with type 1 diabetes mellitus (T1DM) experience, on average,

171 Patients with type 1 diabetes mellitus (T1DM) have a high risk of card

172 Individuals with type 1 diabetes mellitus (T1DM) have a high risk of card

173 Experimental animal models of type 1 diabetes mellitus (T1DM) have advanced these find

174 on of beta cells is the predominant cause of type 1 diabetes mellitus (T1DM) in humans and is modeled

175 cells that is central to the pathogenesis of type 1 diabetes mellitus (T1DM) in humans and the clinic

176 SOD3 and ATP7A in endothelial dysfunction in type 1 diabetes mellitus (T1DM) is entirely unknown.

177 The incidence of type 1 diabetes mellitus (T1DM) is increasing worldwide,

178 The impact of type 1 diabetes mellitus (T1DM) on the developing centra

179 ive proinflammatory mechanisms at and before type 1 diabetes mellitus (T1DM) onset is hindered in hum

180 ences of subclinical coeliac disease (CD) in Type 1 diabetes mellitus (T1DM) remain unclear.

181 c role of gAD in cerebral ischemic injury in type 1 diabetes mellitus (T1DM) remains unclear.

182 Type 1 diabetes mellitus (T1DM) results from an autoimmu

183 Noteworthy in this regard is that type 1 diabetes mellitus (T1DM) results in oxidative str

184 cus (INS VNTR) is the best candidate for the type 1 diabetes mellitus (T1DM) susceptibility locus IDD

185 responsiveness, in young adult subjects with type 1 diabetes mellitus (T1DM) without overt cardiovasc

186 ent antecedent hypoglycemia in patients with type 1 diabetes mellitus (T1DM), 15 patients were studie

187 odel of streptozotocin (STZ)-induced chronic type 1 diabetes mellitus (T1DM), and in non-diabetic (ND

188 ter volumes have been reported in youth with type 1 diabetes mellitus (T1DM), but the effects of hype

189 ensive glycemic control improves outcomes in type 1 diabetes mellitus (T1DM), iatrogenic hypoglycemia

190 oglycemia limits optimal glycemic control in type 1 diabetes mellitus (T1DM), making novel strategies

191 ese diabetic (NOD) mice with overt new-onset type 1 diabetes mellitus (T1DM), short-term treatment wi

192 In type 1 diabetes mellitus (T1DM), T cell-mediated destruc

193 trasound have been reported in patients with type 1 diabetes mellitus (T1DM), the histological spectr

194 insulin-dependent diabetes similar to human type 1 diabetes mellitus (T1DM), whereas the BBDR+/+ rat

195 ically be used to prevent the development of type 1 diabetes mellitus (T1DM)-associated islet autoimm

196 ardial vasodilator function in patients with type 1 diabetes mellitus (T1DM).

197 on of clinical hypoglycemia in patients with type 1 diabetes mellitus (T1DM).

198 of death of insulin-producing beta-cells in type 1 diabetes mellitus (T1DM).

199 riodontal disease is a major complication of type 1 diabetes mellitus (T1DM).

200 nsulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM).

201 es in pancreatic elasticity in children with type 1 diabetes mellitus (T1DM).

202 for restoring normoglycemia in patients with type 1 diabetes mellitus (T1DM).

203 ycemia in healthy subjects and patients with type 1 diabetes mellitus (T1DM).

204 ific protease SENP1 gene develop symptoms of type-1 diabetes mellitus (T1DM), including hyperglycaemi

205 el therapeutic approach for the treatment of Type 1 diabetes mellitus that has the potential to circu

206 Three subjects with unstable type 1 diabetes mellitus underwent islet transplantation

207 ransplantation) and another 28 patients with type 1 diabetes mellitus underwent isolated kidney trans

208 ntation recipients with long-term history of type 1 diabetes mellitus underwent metabolic testing by

209 arch 1993 and August 1998, 111 patients with type 1 diabetes mellitus underwent successful pancreas t

210 Effective glycaemic control in type 1 diabetes mellitus usually requires two or more in

211 ently been achieved in several patients with type 1 diabetes mellitus via pancreatic islet transplant

212 306 clinically diagnosed adult patients with type 1 diabetes mellitus, we developed a prediction mode

213 Using rodent models of type 1 diabetes mellitus, we investigated whether diabet

214 which 1441 subjects aged 13 to 39 years with type 1 diabetes mellitus were randomized to intensive or

215 73 patients with type 1 diabetes mellitus were studied in an open-label,

216 s in driving performance among subjects with type 1 diabetes mellitus when their blood glucose (BG) l

217 ine-hundred three persons with younger-onset type 1 diabetes mellitus who participated in the Wiscons

218 In 85 patients with type 1 diabetes mellitus who underwent SPK or PAK transp

219 plantation (SPKT) is a promising therapy for type 1 diabetes mellitus with chronic kidney disease.

220 T data from 74 healthy eyes and 43 eyes with type 1 diabetes mellitus with mild diabetic retinopathy

221 better outcomes in islet allotransplant for type 1 diabetes mellitus with refinements in immunosuppr